Bivalirudin vs Heparin in NSTEMI and STEMI in Patients on Modern Antiplatelet Therapy in SWEDEHEART

PHASE4CompletedINTERVENTIONAL
Enrollment

6,012

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

March 31, 2017

Study Completion Date

March 31, 2017

Conditions
ST-segment Elevation Myocardial InfarctionNon ST-segment Elevation Myocardial Infarction
Interventions
DRUG

bivalirudin

Will be administered as an intravenous bolus of 0.75 mg per kilogram, followed by an infusion of 1.75 mg per kilogram per hour). Bivalirudin will be administered alone or with a low dose of heparin up to 3000U heparin in lab or up to 5000 U given pre-hospital according to local practice.

DRUG

Heparin

Treatment with unfractionated Heparin 5000 IU/ml i.v. ,Leo Pharma, Sweden, (the control group). Heparin in the control group is administered as an intravenous or intra-arterial bolus according to local practice. A dose of 70-100 U/kg is recommended

Trial Locations (1)

221 85

Lund University, Lund

All Listed Sponsors
collaborator

Lund University

OTHER

lead

Uppsala University

OTHER

NCT02311231 - Bivalirudin vs Heparin in NSTEMI and STEMI in Patients on Modern Antiplatelet Therapy in SWEDEHEART | Biotech Hunter | Biotech Hunter